1 option
Resistance to Ibritumomab in Lymphoma / edited by Makoto Hosono, Jean-François Chatal.
- Format:
- Book
- Series:
- Resistance to targeted anti-cancer therapeutics 2196-5501 ; 18.
- Resistance to Targeted Anti-Cancer Therapeutics, 2196-5501 ; 18
- Language:
- English
- Subjects (All):
- Medicine.
- Cancer--Research.
- Cancer.
- Biomedicine.
- Cancer Research.
- Local Subjects:
- Biomedicine.
- Cancer Research.
- Physical Description:
- 1 online resource (XIII, 158 pages) : 18 illustrations, 14 illustrations in color.
- Contained In:
- Springer eBooks
- Place of Publication:
- Cham : Springer International Publishing : Imprint: Springer, 2018.
- System Details:
- text file PDF
- Summary:
- This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
- Contents:
- Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma
- Biology and Pathology of B-cell lymphoma
- Resistance to Y-90 Ibritumomab Tiuxetan Therapy
- Features of Ibritumomab as Radionuclide Therapy
- Radiological Evaluation of Response and Resistance of Ibritumomab
- Characteristics of Ibritumomab as Radionuclide Therapy Agent
- Resistance and Heterogeneity of Intratumoral Antibody Distribution
- Radiation Dosimetry in Ibritumomab Therapy
- Combining RAIT and immune-based therapies to overcome resistance in cancer?
- Prospects for enhancing efficacy of radioimmunotherapy
- Index.
- Other Format:
- Printed edition:
- ISBN:
- 9783319782386
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.